Sebastian Ricci’s Post

Dispelling the myth that we're far from understanding MPN progression, MPN Research Foundation is at the forefront, driving collaboration across institutions to unlock the mysteries of MPN progression to acute myeloid leukemia (AML).  One of our funded Thrive initiatives, led by Dr. John Crispino in partnership with co-PI, Dr. Ayalew Tefferi of Mayo Clinic, and esteemed collaborators Drs. Charlotte Brierly, Adam Mead, and Beth Psaila, targets the DYRK1A gene on chromosome 21.   This collaborative research uncovers its amplification as a key factor in MPN to AML progression, demonstrating the power of cross-institutional collaboration in advancing our understanding of MPNs.  Supported by our 2022 Thrive award, this study exemplifies our commitment to not just understanding but also interrupting the progression of MPNs, signaling a pivotal leap towards enhancing patient outcomes.  We invite industry professionals and researchers to join our community, gaining insight into the impactful projects we fund and access to the MPN community and foundation-funded research. Together, we can foster groundbreaking discoveries and transformative solutions in the battle against MPNs.  Learn more about our collaborative efforts and how you can be part of this pioneering journey. [ https://lnkd.in/gEfTRRp2 ] Join our community to stay up to date on the latest in MPN funded research, clinical trial highlights, and more: [

🔬 As we observe Oral, Head and Neck Cancer Awareness Week, review our case study on Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma focused on ERGOMED’s Approach to Complex Clinical Trial Management. By raising awareness and fostering collaborative efforts, we're driving progress in the fight against head and neck cancers. Join us in recognizing the collective effort and commitment to advancing treatments for those impacted by head and neck cancers. Read case study: https://lnkd.in/gfGxfnym #OHANCAW #OralCancerAwareness #HeadAndNeckCancer #ClinicalResearch

Results from the phase III KRYSTAL-12 trial were presented by Dr. Tony Mok during the 2024 ASCO Annual Meeting. Read a recap in ILCN: https://bit.ly/3xrtdhh #LCSM

HUTCHMED Highlights Publication of Phase III ESLIM-01

HUTCHMED Highlights Publication of Phase III ESLIM-01

HUTCHMED Highlights Publication of Phase III ESLIM-01

It's finally here! 😁 Our new paper on platelet diagnostics! 😃 👇 https://lnkd.in/daf6HcuT

Schedule a meeting with the experts from Discovery Life Sciences at #ASCO24

Hello friends! Our lab and the study I helped collaborate on was discussed in VT news today. If you would like to read it, I have copied the link below https://lnkd.in/e3kswuiH

Ready for ASCO? Dive into the findings of the IMROZ trial in Multiple Myeloma with our newest blog from Zachary Moore https://lnkd.in/gA_swWEa